Machine signal
Active cluster sell — 3 distinct insiders, $2.1M, window ends Sep 16, 2026.
Figures computed from official regulatory filings — .
Analysttarget 44.08 USD (+260%) · consensus 4.86/5 · 14 buy · 0 hold · 0 sell
Ownershipinsiders 1.69% · institutions 133.73% · short 21.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Avalo Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
576 buys46 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lind Kevin Robert | AwardD (derivative) | $16.6K | Unusual size |
| Jain Rita | AwardD (derivative) | $16.2K | Unusual size | SEC |
| Philip Ron M | AwardD (derivative) | $13.6K | Unusual size | SEC |
| Sullivan Christopher Ryan | Exercise | $122.5K | SEC |
| Sullivan Christopher Ryan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sullivan Christopher Ryan | Sell | $202.4K | SEC |
| Sullivan Christopher Ryan | Exercise | $81.9K | SEC |
| Sullivan Christopher Ryan | Sell | $179.5K | SEC |
| Sullivan Christopher Ryan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Doyle Mittie | Sell | $13.6K | SEC |
| Doyle Mittie | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Doyle Mittie | Exercise | $5.5K | SEC |
| Doyle Mittie | Sell | $20K | SEC |
| Doyle Mittie | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sullivan Christopher Ryan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sullivan Christopher Ryan | Exercise | $374.9K | SEC |
| Doyle Mittie | Exercise | $12.7K | SEC |
| Sullivan Christopher Ryan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sullivan Christopher Ryan | Sell | $622.3K | Unusual size | SEC |
| Sullivan Christopher Ryan | Sell | $74.8K | SEC |
| Sullivan Christopher Ryan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sullivan Christopher Ryan | Exercise | $28.4K | SEC |
| Sullivan Christopher Ryan | Sell | $753.3K | Unusual size | SEC |
| Sullivan Christopher Ryan | Exercise | $306.6K | SEC |
| Doyle Mittie | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |